checkAd

    DGAP-News  535  0 Kommentare MOLOGEN AG presented subgroup analysis from IMPACT study and design of pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015


    DGAP-News: MOLOGEN AG / Key word(s): Study/Study results
    MOLOGEN AG presented subgroup analysis from IMPACT study and design of
    pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015

    19.01.2015 / 08:00

    ---------------------------------------------------------------------

    MOLOGEN AG presented subgroup analysis from IMPACT study and design of
    pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015

    Berlin, January 19, 2015 - The biotechnology company MOLOGEN AG presented
    two posters on the cancer immunotherapy MGN1703 at the Gastrointestinal
    Cancers Symposium 2015 in San Francisco, California. The first poster
    featured promising data on overall survival of patient subgroups from the
    IMPACT study in colorectal cancer. The data suggests that responders to
    induction therapy may benefit the most from a switch maintenance treatment
    with MGN1703. This is reflected in the pivotal study IMPALA where 'response
    to induction therapy' is one of the main inclusion criteria. The second
    poster outlined the design of the IMPALA trial, which has been already
    started in 2014 and is currently enrolling patients.

    "We are pleased that the predictive factors previously shown to indicate a
    more promising progression free survival are also applicable for overall
    survival. The IMPALA study design is based on these findings. IMPALA will
    only include patients with response after induction therapy. These patients
    seem to be the best candidates to benefit most from the MGN1703
    immunotherapy," said Prof. Dr. Dirk Arnold, MD, Director of the Clinic for
    Medical Oncology, Klinik für Tumorbiologie, Freiburg, Germany. He is one of
    the study investigators of IMPACT, one of the coordinating study
    investigators of IMPALA and also a member of the steering committee of
    IMPALA.

    Further to the IMPALA trial in colorectal cancer, MGN1703 is being
    investigated for first-line maintenance treatment of extensive-stage small
    cell lung cancer, a serious cancer disease with high unmet medical need.
    IMPULSE, an international randomized controlled trial, is currently
    enrolling patients as well.


    About IMPACT
    IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal
    Carcinoma with Disease Control after Initial First-line Therapy) was a
    phase II, randomized, placebo-controlled, double-blind, multicenter
    clinical study aiming to determine the efficacy of MGN1703 as switch
    maintenance therapy following first-line chemotherapy with or without the
    antibody bevacizumab in patients with metastatic colorectal cancer.
    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News MOLOGEN AG presented subgroup analysis from IMPACT study and design of pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015 DGAP-News: MOLOGEN AG / Key word(s): Study/Study results MOLOGEN AG presented subgroup analysis from IMPACT study and design of pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015 19.01.2015 / 08:00 …